Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bothrops-crotalus antivenom
- Development stage
- Phase 2
- Lead developer
- Instituto Butantan
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Bothrops-Crotalus antivenom** (soro antibotrópico-crotálico) is a bivalent, equine-derived antivenom designed to neutralize the venoms of pit vipers (*Bothrops* spp.) and rattlesnakes (*Crotalus* spp.). It is primarily indicated for the treatment of snakebite envenomings in Brazil, where it is manufactured by public institutions such as the Butantan Institute, Vital Brazil Institute, and Fundação Ezequiel Dias (FUNED) under the coordination of the Brazilian Ministry of Health. The antivenom consists of purified F(ab')2 immunoglobulin fragments that bind and neutralize toxic venom components, including metalloproteinases, serine proteases, phospholipases A2, and crotoxin. While standard formulations are liquid and require a cold chain, some clinical trial contexts associate this name with an experimental freeze-dried trivalent antivenom (FDTAV) developed by the Army Institute of Biology (IBEx) and Butantan Institute, which also neutralizes *Lachesis* venoms to enable cold-chain-free storage in remote regions like the Amazon.
- Other names
- soro antibotrópico-crotálicoBothrops-Crotalus bivalent antivenom
02
Targets
CTX (Crotoxin complex and other Crotalus neurotoxins)svPLA2 (Snake venom phospholipase A2)SVMP (Snake venom metalloproteinase class P-III)Bothrops venom
Beyond the preview
Go deeper on bothrops-crotalus antivenom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bothrops-crotalus antivenom.